Actively Recruiting
Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial
Led by Mayo Clinic · Updated on 2026-05-11
141
Participants Needed
1
Research Sites
214 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial evaluates the effect of radiotherapy doses based on tumor size and tumor-specific characteristics (biologically-adapted) in treating patients with Ewing sarcoma. Radiotherapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Conventional radiotherapy uses minimal imaging support to determine the positioning of radiotherapy. Hypofractionated radiotherapy delivers higher doses of radiotherapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Dose-escalated radiotherapy uses doses that are higher than those used in conventional radiotherapy. Larger tumor sizes and other tumor-specific characteristics have been shown to be related to poorer outcomes. In addition, after dose-escalated radiotherapy, patients with larger tumors have demonstrated improved control of the disease at the primary tumor site. Giving biologically-adapted, dose-escalated radiotherapy may reduce the return of the cancer at the primary tumor site in patients with Ewing sarcoma with large tumors and other unfavorable characteristics. This clinical trial also evaluates the role of biomarkers in patients with Ewing sarcoma. Studying samples of blood and tumor tissue from patients with Ewing sarcoma in the laboratory may help doctors learn more about predicting the amount of disease and the likelihood of the cancer coming back.
CONDITIONS
Official Title
Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological confirmation of Ewing sarcoma, including both skeletal and extra-skeletal primary tumors, or "Ewing-like" sarcoma if treated per Ewing treatment guidelines
- Patients aged 2 years or older
- Lansky or Karnofsky performance status of 70 or higher
- Ability to provide written informed consent and complete questionnaires, with or without assistance
- Willingness to provide blood samples for research
- For Cohort A only: willingness to provide a biopsy sample for the Mayo Complete Solid Tumor Panel
You will not qualify if you...
- Prior chemotherapy or radiotherapy that interferes with current treatment or outcome measurement as determined by treating doctors
- Receiving investigational agents that interfere with current treatment or outcome measurement, unless allowed by radiation oncologist
- Active malignancy within 1 year before registration that interferes with treatment or outcomes
- Severe systemic illness or other disease interfering with treatment or outcomes
- Active uncontrolled infection, symptomatic heart failure, unstable angina, cardiac arrhythmia, psychiatric illness, or social situation limiting study adherence
- Pregnancy or nursing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
C
Clinical Trials Referral Office
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here